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Abstract 
Introduction: The aim of this study was to explore the association between thyroid hormones and abdominal fat quantities in euthyroid 
post-menopausal women.
Material and methods: Serum levels of thyroid stimulating hormone (TSH), free triiodothyronine (fT3), and free thyroxine (fT4) as well 
as body mass index (BMI) and waist circumference (WC) were collected from 540 euthyroid post-menopausal women aged 45–65 years. 
Magnetic resonance imaging (MRI) was performed to measure visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) area. 
Multivariate linear regression analysis was used to determine whether abdominal fat was associated with thyroid hormones.
Results: Weight, BMI, WC, fasting plasma glucose (FPG), fasting insulin (Fins), homeostasis model assessment of insulin resistance 
(HOMA-IR), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), TSH, and fT4 were higher in the obese group than in the non-
obese group (p < 0.05). The study participants were divided into four groups according to quartiles in the light of TSH reference range 
(0.1–4.2 mU/L). Subcutaneous adipose tissue and VAT increased with the TSH levels. Adjusted for age, years since menopause (YSM), 
BMI, and HOMA-IR, VAT was negatively correlated with fT4 and positively correlated with fT3 and fT3-to-fT4 ratio (fT3/fT4) (p < 0.05), 
while no association was found between SAT and thyroid hormones. Similarly, we found no relation between body fat distribution and 
TSH. Furthermore, the association of common indicators of obesity and thyroid hormones showed no significance.
Conclusions: In euthyroid post-menopausal women, VAT rather than SAT was negatively correlated with fT4, and positively correlated 
with fT3 and fT3/fT4. (Endokrynol Pol 2020; 71 (4): 299–305)
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Introduction
Obesity has been identified as a major modifiable risk 
factor associated with morbidity and mortality. The 
prevalence of obesity has increased dramatically as 
one of the most common worldwide health problems 
in recent decades. More than 1.4 billion adults aged 20 
years or older are overweight. Of these, over 200 million 
men and nearly 300 million women are obese [1]. The 
prevalence of overweight and obesity among Chinese 
adults was 42.6% in 2010 [2], and it increased with age.
The prevalence of obesity is even more serious in 
post-menopausal women due to the decline of oes-
trogen levels [3], the increase of follicle-stimulating 
hormone (FSH) levels [4], and the reduction in en-
ergy expenditure [5]. Furthermore, other endogenous 
hormones like thyroid hormones also contributed to 
post-menopausal obesity [6–8]. However, it was com-
plicated to evaluate the effect of thyroid hormones on 
weight gain in the post-menopausal status, especially 
when using traditional indicators of fat mass like body 
mass index (BMI) and waist circumference (WC). Firstly, 
the serum thyroid stimulating hormone (TSH) concen-
tration and prevalence of thyroid dysfunction increased 
along with aging and menopause for the diminution 
of size, iodine absorption ability, and daily produc-
tion of triiodothyroxine (T3) and thyroxine (T4) of the 
thyroid gland [9, 10]. Secondly, the post-menopausal 
women underwent body fat changes characterised by 
weight gain in general fat mass and, mainly, central 
adiposity [11, 12]. Toth et al. [13] reported an increase 
of 49% in abdominal fat and 22% in subcutaneous fat 
in post-menopausal comparing to premenopausal 
women. Body mass index and WC, used as common 
indicators of obesity, could hardly distinguish the 
distribution of body fat in post-menopausal women. 
Based on the above-mentioned reasons, the relationship 
between thyroid hormones and general obesity (BMI, 
WC) as well as regional adiposity indicated as visceral 
adipose tissue (VAT) and subcutaneous adipose tissue 
(SAT) area remain a focus of debate both in thyroid 
dysfunction and euthyroid individuals [14–18]. 
Because obesity is known as a risk factor of cardiovas-
cular disease and all-cause mortality, the determination 
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munoassay kits (Tianjin Jiuding Medical Bioengineering Co., Ltd., 
Tianjin, China).
MRI quantification of the VAT and SAT
MRI examination was performed by a 1.5-T scanner (Magnetom 
Open Viva, Siemens AG, Erlangen, Germany). The quantification 
of abdominal fat was detected at the level of the L3–L4 discs. 
SliceOmatic image analysis software (version 4.3, Tomovision, Mon-
treal, CA) was used to analyse MRI slices. VAT and SAT areas (cm2) 
were measured separately by two observers. The correlation coeffi-
cient of observer variation was 0.816 (p < 0.001). A repeated measure-
ment was conducted by a third observer to assess the repeatability. 
Statistical analysis
The data of normal distribution were expressed as mean ± SD, 
while the data of non-normal distribution were presented as me-
dians with inter-quartile range. The comparison of two groups was 
performed by Student’s t-test for normal distribution and by Mann–
Whitney U test for non-normal distribution. A test for linear trend 
was conducted with the quartiles of median values of serum TSH 
as a continuous variable in the models. A multiple liner regression 
analysis was constructed to investigate the relationship between 
abdominal obesity indices measured by MRI (SAT area and VAT 
area) and thyroid hormones. Model 1 is the crude model. Model 2 
is adjusted for age, years since menopause, and oestrogens. Model 
3 is further adjusted for HOMA-IR and BMI. Statistical analysis was 
performed by SPSS17.0 software. All variables with a p-value less 
than 0.05 were considered as statistically significant.
Results
A total of 540 post-menopausal women (55.00 ± 9.15 
years) were included in the study. All the subjects were 
divided into an obese group and non-obese group ac-
cording to whether their BMI was greater than 28 kg/m2 
or not. 224 (41.48%) and 316 (58.52%) objects were obese 
and non-obese. No significant differences were seen in 
variables such as age, YSM, height, systolic blood pressure 
(SBP), diastolic blood pressure (DBP), HDL-C, HbA1c, and 
fT3 (p > 0.05). Weight, BMI, WC, FPG, Fins, HOMA-IR, 
LDL-C, TG, TSH, and fT4 were higher in the obese group 
than in the non-obese group (p < 0.05) (Tab. 1).
Thyroid stimulating hormone was divided into 
four groups according to quartiles in light of the TSH 
reference range (0.1–4.2 mIU/L). The numbers of objects 
were 97 (18%), 152 (28%), 155 (29%), and 136 ( 25%), 
respectively, in four groups. The SAT and VAT areas 
increased with the TSH levels (p < 0.05), while age, BMI, 
WC, HOMA-IR, LDL-C, and TG levels increased with 
TSH levels without any significant difference (p > 0.05). 
However, other variables in the four groups showed no 
significant differences (Tab. 2).
A multiple liner regression analysis was performed 
to identify which thyroid hormones had a major role 
in determining the VAT and SAT. Visceral adipose 
tissue was negatively correlated with fT4 and posi-
tively correlated with fT3 and fT3-to-fT4 ratio (fT3/fT4) 
(p < 0.05), even after adjusting for possible confounders 
of age, years since menopause, oestrogens (model 2), 
of potential risk factors of anatomical fat accumulation 
during this period of women’s lives is an important health 
target. To our knowledge, the evidence of the relationship 
between normal thyroid function and central obesity 
assessed by MRI remain scarce. With this background, 
the present research explored the relationship between 
serum thyroid hormones and obesity determined by 
MRI in a sample of euthyroid post-menopausal women.
Material and methods
Subjects
Data were obtained from a cross-sectional survey in post-meno-
pausal women aged 45–65 years in the community of Banknote 
Printing Company of Chengdu. Age, years since menopause 
(YSM), and chronic medical histories of subjects were recorded in 
a face-to-face questionnaire survey conducted by trained medical 
staff before enrolment. Women with a history of post-menopause 
for 1–9 years, who were willing to participate in this study, were 
included. Patients were excluded in any of the following circum-
stances: hysterectomy, hormone replacement therapy, thyroidec-
tomy, taking medications affecting thyroid function, and heart, 
renal, or liver failure. Finally, a total of 540 women were recruited 
to the investigation. All the subjects signed informed consent for 
the questionnaire survey and data collection for research purposes. 
This study was approved by the Ethics Committee of the Fifth 
People’s Hospital of Chengdu and was conducted in accordance 
with the Declaration of Helsinki.
Diagnosis criteria
Menopause referred to 12 consecutive months of amenorrhoea 
without using hormonal contraception, according to the National 
Institute of Health and Care Excellence guideline [19]. Overweight 
and obesity prevention and control guideline for Chinese adults 
(2003 edition) formulated by the Ministry of Health was used as the 
diagnostic criteria for obesity [20]. Obesity was defined as BMI ≥ 28 
kg/m2. Euthyroidism was defined as serum TSH (0.1–4.2 mU/L), fT3 
(2–6 pmol/ L), and fT4 (12–24 pmol/L) levels within our laboratory 
references ranges, without history of thyroid diseases, taking TH 
replacement therapy, and anti-thyroid drugs.
Clinical and biochemical measurements
All the subjects were submitted to take a physical examination in-
cluding height, weight, and waist circumference (WC) measurement 
with unlined clothes and barefoot with an empty stomach. WC was 
assessed at the horizontal circumference between the midline of the 
iliac crest and the lower edge of the 12th rib. Body mass index was 
calculated as weight [kg] / height [m2]. After sitting for 15 minutes, the 
blood pressure of the brachial artery in the right arm was measured 
with a mercury sphygmomanometer three times, with intervals of 
more than five minutes, and the mean value was obtained.
After 12 hours of fasting, blood samples were taken from the fore-
arm vein at 8~10 a.m. the next morning. The serum fasting plasma 
glucose (FPG), fasting insulin (Fins), triglycerides (TG), low-density 
lipoprotein (LDL-C), high-density lipoprotein (HDL-C), and gly-
cated haemoglobin (HbA1c) were measured by an Olympus AU 5400 
automatic biochemical analyser (Japan). Serum TSH and fT4 were 
measured by Enzyme Linked Immunosorbent Assay (Bayer Co., 
Tokyo, Japan). Homeostasis model assessment of insulin resistance 
(HOMA-IR) was calculated as follows: 
HOMA-IR = (Fins [mIU/L]) × (FPG [mmol/L] / 22.5) 
Serum levels of oestradiol (E2), luteinising hormone (LH), and 
follicle stimulating hormone (FSH) were measured by radioim-
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HOMA-IR, and BMI (model 3). In contrast, SAT area 
was not associated with thyroid hormones (p > 0.05) 
(Tab. 3). Similarly, the association of common indicators 
of obesity (BMI, WC) and thyroid hormones showed 
no significance (data not shown).
Discussion
In this cross-sectional study of 540 euthyroid post-meno-
pausal women, we have demonstrated that VAT rather 
than SAT was negatively correlated with fT4 and 
positively correlated with fT3 and fT3/fT4. However, 
common parameters of obesity assessed by BMI and 
WC were not associated with thyroid hormones. Fur-
thermore, we found no relation between body fat dis-
tribution and TSH.
The association of thyroid hormones with fat 
distribution has been studied previously [17, 18, 21]. 
Muscogiuri et al. [17] demonstrated that VAT quantified 
by CT was the best predictor of TSH concentration in 
obesity. Akbaba et al. [18] found that VAT was positively 
correlated with fT4 in subclinical hypothyroidism. Min 
et al. [21] indicated that fT3 and fT4 were significantly 
associated with increased pericardial fat volume and 
BMI in non-obese euthyroid men. In concordance 
with those investigations, we found that fT3 and fT4 
levels were inversely correlated with VAT in euthyroid 
post-menopausal women. The pathogenesis of the 
relationship between thyroid hormones and obesity 
in post-menopausal states has not yet been fully eluci-
dated. Some underlying mechanisms might be explored 
as follows: First, both thyroid hormones and leptin af-
Table 1. Comparison of clinical characteristics of none-obese and obese participants
Variables All None-obese Obese p
N (%) 540 316 (58.52%) 224 (41.48%) NS
Age [years] 55.00 ± 9.15 54.74 ± 7.43 56.23 ± 10.03 0.081
YSM [years] 4.17 ± 1.56 5.11 ± 1.21 4.07 ± 1.42 0.561
Height [cm] 157.08 ± 16.40 156.4 ± 14.61 158.11 ± 17.72 0.668
Weight [kg] 68.51 ± 11.32 57.89 ± 10.52 71.26 ± 9.27 0.060
BMI [kg/m2] 24.48 ± 3.52 21.63 ± 3.37 28.27 ± 4.41 < 0.001
WC [cm] 80.55 ± 10.34 77.71 ± 9.98 84.25 ± 9.61 < 0.001
SBP [mmHg]  131.89 ± 21.67 134.27 ± 20.63 130.07 ± 22.27 0.054
DBP [mmHg] 79.43 ± 13.15 82.16 ± 13.02 77.35 ± 12.86 0.615
E2 [pg/mL] 13. 12 ± 8. 34 14. 82 ± 8. 54 12. 51 ± 7. 69 0.227
LH [mIU/mL] 24.52 ± 14.06 25.67 ± 23.09 23.16 ± 31.09 0.089
FSH [mIU/mL] 59.39 ± 37.02 62.95 ± 41.09 58.95 ± 39.47 0.055
HbA1c 6.38 [1.31] 5.75 [1.17] 7.14 [1.27] 0.067
FPG [mmol/L] 8.15 ± 1.16 5.31 ± 1.09 8.97 ± 2.12 0.028
Fins [mU/L] 9.11 ± 1.98 8.18 ± 1.51 15.87 ± 4.42 0.042
HOMA-IR* 1.18 (0.91) 0.88 (0.79) 1.23 (0.82) 0.019
LDL [mmol/L] 3.27 ± 0.61 3.10 ± 0.66 3.68 ± 0.92 0.026
HDL [mmol/L] 1.61 ± 0.42 1.74 ± 0.52 1.41 ± 0.45 0.782
TG [mmol/L]* 1.29 (0.97) 1.32 (0.74) 1.91 (1.02) 0.014
TSH [mU/L] * 3.15 (1.42) 2.16 (1.28) 4.15 (2.58) 0.045
fT3 [pmol/L] * 3.84 (1.09) 3.24 (0.88) 4.72 (1.48) 0.059
fT4 [pmol/L] * 15.89 ± 3.12 14.21 ± 4.34 21.11 ± 3.57 0.042
SAT area [cm2] 166.8 ± 82.7 152.4 ± 39.1 197.4 ± 58.2 0.023
VAT area [cm2] 75.4 ± 31.1 65.4 ± 20.1 84.4 ± 26.1 0.018
Data were expressed as mean ± SD unless indicated otherwise. Normal distribution variables were compared by Student’s t-test. YSM — years since menopause; 
BMI — body mass index; WC — waist circumference; SBP — systolic blood pressure; DBP — diastolic blood pressure; TG — triglycerides; HDL-C — high-density 
lipoprotein-cholesterol; LDL-C — low-density lipoprotein-cholesterol; FPG — fasting plasma glucose; HbA1c — glycated haemoglobin; Fins — fasting insulin; 
TSH — thyrotropin; fT3 — free triiodothyronine; fT4 — free thyroxine; E2 — oestradiol; LH — luteinising hormone; FSH — follicle-stimulating hormone; 
SAT — subcutaneous adipose tissue; VAT — visceral adipose tissue. p < 0.05 is considered as significant level. *Non-normal distribution data are presented  
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Table 2. Clinical and biochemical characteristics of euthyroid subjects according to the quartiles of serum thyroid-stimulating 
hormone (TSH) levels within the reference range
Variables
TSH [mU/L] 
1st quartile 2nd quartile 3rd quartile 4th quartile pbTrend 
N 97(18%) 152(28%) 155(29%) 136(25%) NS
TSH [mU/L] 1.88 (0.79) 2.95 (0.61) 3.11 (0.81) 4.09 (0.76) 0.012
Age (years) 48.34 ± 11.43 53.92 ± 10.22 57.04 ± 9.69 68.34 ± 11.12 0.063
YSM (years) 4.20 ± 1.12 5.01 ± 0.98 4.77 ± 1.25 6.58 ± 1.78 0.451
BMI [kg/m2] 23.81 ± 2.18 24.89 ± 2.42 27.22 ± 4.18 29.12 ± 3.11 0.062
WC [cm] 80.92 ± 8.94 82.13 ± 11.13 86.09 ± 10.21 88.18 ± 9.21 0.067
SBP [mm Hg] 129.13 ± 18.33 129.94 ± 19.27 131.09 ± 20.52 133.22 ± 21.03 0.084
DBP [mm Hg] 80.19 ± 10.12 79.99 ± 12.63 81.23 ± 12.36 80.72 ± 10.56 0.081
FPG [mmol/L] 80.19 ± 10.12 79.99 ± 12.63 81.23 ± 12.36 80.72 ± 10.56 0.081
E2 [pg/mL] 13.09 ± 7.11 14.00 ± 6.98 12.83 ± 6.60 14.14 ± 7.61 0.227
LH [mIU/mL] 25.12 ± 13.89 25.99 ± 24.09 24.06 ± 20.19 23.88 ± 29.19 0.089
FSH [mIU/mL] 61.39 ± 37.02 60.95 ± 31.29 58.95 ± 39.55 57.79 ± 30.01 0.055
HbA1c 6.12 (1.74) 5.95 (1.07) 6.82 (1.12) 7.01 (1.56) 0.441
Fins [mU/L] 8.89 ± 1.26 10.08 ± 1.05 14.11 ± 2.93 18.21 ± 2.52 0.689
HOMA-IRa 0.75 (0.53) 1.16 (0.67) 1.29 (0.87) 1.32 (0.79) 0.055
LDL-C [mmol/L] 3.09 ± 0.37 3.18 ± 0.79 3.44 ± 1.09 3.81 ± 0.98 0.068
HDL-C [mmol/L] 1.51 ± 0.23 1.49 ± 0.52 1.54 ± 0.66 1.47 ± 0.62 0.073
TG [mmol/L] 1.21 (0.77) 1.52 (0.82) 1.78 (0.89) 1.98 (0.74) 0.094
fT3 [pmol/L]a 4.15(0.79) 3.62(1.28) 4.02(1.16) 3.881(1.48) 0.129
fT4 [pmol/L]a 19.19 ± 4.55 16.28 ± 3.78 15.45 ± 4.12 14.11 ± 4.42 0.062
SAT area [cm2] 149.81 ± 44.17 155.14 ± 41.21 170.04 ± 48.22 181.71 ± 50.28 0.046
VAT area [cm2] 62.45 ± 26.32 71.92 ± 35.16 81.42 ± 29.16 95.72 ± 32.36 0.021
Data were expressed as mean ± SD unless indicated otherwise; aNon-normal distribution data; bTest for trends across ordered groups. Abbreviations listed in Table 1
Table 3. Association of thyroid hormones as independent variables with visceral adipose tissue (VAT) and subcutaneous adipose 
tissue (SAT) area by multiple regression analysis 
Variables
Model 1 Model 2 Model 3
b (95% CI) p b (95% CI) p b (95% CI) p 
VAT area [cm2]
TSH [mU/L] 1.003 (0.832,1.128) 0.089 0.755 (0.592,1.008) 0.051 0.811 (0.735,1.105) 0.063 
fT3 [pmol/L] 1.103 (1.032,1.341) 0.013 1.213 (1.187,1.355) 0.045 1.147 (1.099,1.248) 0.048 
fT4 [pmol/L] –1.562 (–1.271,–1.692) 0.038 –1.312 (–1.063,–1.452) 0.044 –1.420 (–1.203,1.595) 0.040 
fT3/fT4 1.141 (1.072,1.253) 0.016 1.377 (1.282,1.465) 0.021 1.198 (1.002,1.312) 0.033 
SAT area [cm2]
TSH [mU/L] 1.013 (0.742,1.109) 0.545 0.883 (0.946,1.273) 0.665 0.932 (0.844,1.004) 0.832 
fT3 [pmol/L] 1.603 (0.942,1.818) 0.618 1.121 (0.712,1.308) 0.753 0.877 (0.615,1.017) 0.673 
fT4 [pmol/L] 1.403 (0.927,1.605) 0.463 1.223 (0.804,1.415) 0.662 0.993 (0.716,1.118) 0.553 
fT3/fT4 0.803 (0.682,1.024) 0.849 0.553 (0.421,1.001) 0.728 0.613 (0.599,1.128) 0.940 
Values of b are standardised regression coefficients; Model 1 — crude model; Model 2 — adjustment for age, years since menopause, estrogens; Model 3 — further 
adjustment for HOMA-IR and BMI; Abbreviations listed in Table 1
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fected each other and regulated body composition [22, 
23], but the changes of serum leptin in post-menopausal 
women remained contradictory as either increased [24], 
identical [25] or decreased [26]. Hence, further studies 
are needed to demonstrate how leptin influences thy-
roid hormones in post-menopausal women. Second, 
a decreased expression of DIO2 in adipose tissues of 
obese individuals led to a lower local conversion of T4 
to T3, resulting in elevated serum fT3 as a compensation 
of peripheral hormone resistance [27]. Third, clinically 
euthyroid obese patients had decreased expression of 
TSHR and TRα1 in VAT and SAT in the face of higher 
plasma fT3 and TSH, which would be reversed after 
major weight loss [28]. 
Interestingly, we did not find any correlation be-
tween SAT and thyroid hormones. Alevizaki’s [15] 
findings showed that SAT was negatively associated 
with fT4 and positively associated with TSH among 
euthyroid overweight individuals. Westerink et al. [29] 
observed that TSH levels in the normal range were asso-
ciated with an increase in VAT in patients with vascular 
diseases over 66 years old. Firstly, this could be partially 
explained by the different functional characteristics of 
abdominal VAT and SAT with diverse physiological and 
metabolic responses in handling excess fat [30]. VAT 
was a major endocrine organ that secreted a variety of 
cytokines and adipocytokines, which interfered with 
the HPT axis. On the basis of this findings, whether 
post-menopausal status might modify the relationship 
between anatomic body fat and thyroid hormones 
continues to be debated. Further longitudinal studies 
are needed to assess the interrelationship between the 
hypothalamic–pituitary–thyroid axis and fat redistribu-
tion in post-menopausal women over time.
In addition, studies have shown that abdominal VAT 
and SAT are major contributors to insulin resistance 
[31, 32], while gluteofemoral fat is protective against 
diabetes and cardiovascular disease [33]. However, the 
current study focuses on abdominal adipose and does 
not include the thoracic adipose and peripheral subcu-
taneous adipose in upper and lower extremities. Mean-
while, we evaluated only the abdominal section of SAT 
instead of the total subcutaneous fat volume. Hence, it 
was difficult to extend our results to the relationship 
between other ectopic fat distribution and thyroid hor-
mones. Accordingly, further investigations are needed 
to clarify the association of thyroid function parameters 
with other anatomic fat accumulation. 
The correlations between serum TSH within the 
reference range and obesity revealed conflict. Several 
studies indicated that TSH was positively correlated 
with obesity in euthyroid subjects [8, 34]. However, 
a meta-analysis showed that only 18 out of 29 studies 
found a positive association between TSH and obesity, 
while others did not [35]. Our study was in accordance 
with previous research that showed no association be-
tween TSH and obesity assessed by both general (BMI 
and WC) [36] and abdominal (VAT and SAT) indicators 
[18]. The discrepant results among different studies can 
be attributed to different study designs, analyses, and 
varying control of confounding variables. First, aging 
was considered as a potential confounder of the associa-
tion between obesity and thyroid hormones. Accord-
ingly, various cross-sectional and longitudinal studies 
suggested an age-related increase in the TSH set point 
and a reduction of fT4 level for decreased synthesis 
and catabolism of fT4 [37–39]. The present study only 
enrolled post-menopausal women aged 45–65 years to 
reduce the confounding factor of aging, although it is 
difficult to fully control the influence in a cross-sectional 
design. Second, it was observed that the association be-
tween TH and obesity was different among individuals 
with varying degrees of obesity [40]. The correlations 
of BMI and serum TSH concentration was shown 
among morbidly obese participants [41], which would 
be attenuated in lean women. The average BMI of our 
sample was 24.48, far less than other studies. Third, the 
normal range of the TSH has been the subject of intense 
debate among numerous studies. This variability in the 
reference interval might explain the lack of association 
between TSH and indicators of obesity. Forth, there is 
a special, individual set point for pituitary-thyroid axis 
function, and the reference ranges of TSH are altered 
with age. 
The strengths of this study are that quantitative 
determination of VAT and SAT were precisely as-
sessed by MRI, which more accurately described the 
body fat distribution in post-menopausal women. We 
performed multivariable adjusted analyses for age, 
years since menopause, oestrogens, HOMA-IR, and 
BMI in healthy euthyroid post-menopausal women, 
which provided well-characterised data and ensured 
relatively reliable evaluations. However, there were 
some limitations to the present study. First, we can-
not indicate causality between VAT and SAT area 
and thyroid hormones for the cross-sectional design. 
Second, all the participants enrolled were Chinese 
post-menopausal women. Third, thyroid antibodies 
considered as common confounders were not taken 
into account. Forth, we only included subjects with 
euthyroidism rather than without thyroid disorders 
because thyroid ultrasonography and anti-thyroid 
antibodies were not checked in the present study. Thus, 
follow-up research with expanded sample sizes and 
with patients of normal thyroid structure and function 
should be conducted to obtain more scientific data to 
clarify the impact of hormone changes, age, and other 
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Taken together, our study highlighted that VAT 
rather than SAT was negatively correlated with fT4 
and positively correlated with fT3 and fT3-to-fT4 ra-
tio (fT3/fT4) in Chinese euthyroid post-menopausal 
women. Our results suggest that slight differences in 
thyroid function parameters might reflect increasing 
intra-abdominal fat. Further longitudinal studies are 
needed to better understand the causality between 
serum levels of fT4 or fT3 and regional adiposity in 
euthyroid post-menopausal women.
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